Yu Yao

4.5k total citations · 2 hit papers
104 papers, 2.3k citations indexed

About

Yu Yao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yu Yao has authored 104 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Yu Yao's work include Lung Cancer Treatments and Mutations (18 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Lung Cancer Research Studies (11 papers). Yu Yao is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Lung Cancer Research Studies (11 papers). Yu Yao collaborates with scholars based in China, United States and Spain. Yu Yao's co-authors include Amer Assal, Xingxing Zang, Eszter Lázár‐Molnár, Kim C. Ohaegbulam, Yi Shao, Junmin Qian, Aili Suo, Tao Tian, Wanggang Zhang and Xuan Liang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yu Yao

93 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

2014 654 citations Yu Yao et al. profile →
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 201 citations Yongliang Zhang, Yu Yao et al. Nature Communications profile →

Peers

Countries citing papers authored by Yu Yao

Since Specialization

Citations

This map shows the geographic impact of Yu Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Yao more than expected).

Fields of papers citing papers by Yu Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Yao. The network helps show where Yu Yao may publish in the future.

Co-authorship network of co-authors of Yu Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Yao. A scholar is included among the top collaborators of Yu Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Yao. Yu Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Reversing MET‐Mediated Resistance in Oncogene‐Driven NSCLC by MET‐Activated Wnt Condensative Prodrug	Advanced Science	Na Liu, Xiaoqiang Zheng et al.	5
2	MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC	Journal of Thoracic Oncology	Natalia Valdiviezo, Pasi A. Jänne et al.	5
3	Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial	Cancer Research	Ying Cheng, Lin Wu et al.	5
4	Social support and depressive symptoms among migrant elderly following children: the chain mediating role of resilience and loneliness	BMC Psychiatry	Haixia Liu, Yu Yao et al.	0
5	Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels	Journal of Immunotherapy	Ni Zhao, Aimin Jiang et al.	3
6	A novel risk classifier to predict the in-hospital death risk of nosocomial infections in elderly cancer patients	Frontiers in Cellular and Infection Microbiology	Aimin Jiang, Yimeng Li et al.	2
7	Establishment of a risk classifier to predict the in-hospital death risk of nosocomial fungal infections in cancer patients	BMC Infectious Diseases	Ruoxuan Wang, Aimin Jiang et al.	2
8	Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis	Frontiers in Cardiovascular Medicine	Xue Chen, Aimin Jiang et al.	22
9	Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis	Cancer Control	Aimin Jiang, Haoran Zheng et al.	5
10	Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study	Cancer Control	Aimin Jiang, Na Liu et al.	7
11	Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases	Thoracic Cancer	Jinyao Zhang, Yan Wang et al.	23
12	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients breakdown →	Nature Communications	Yongliang Zhang, Yu Yao et al.	201
13	Perioperative risk factors for recovery room delirium after elective non-cardiovascular surgery under general anaesthesia	SHILAP Revista de lepidopterología	Jiayi Wu, Shao‐Jie Gao et al.	15
14	<p>PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer</p>	Cancer Management and Research	Xiao Fu, Zhiyan Liu et al.	10
15	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors	Journal of Experimental & Clinical Cancer Research	Xiaohui Jia, Panpan Jiang et al.	82
16	Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China	BMC Infectious Diseases	Aimin Jiang, Xin Shi et al.	30
17	EP1.12-22 The Expression and Prognostic Roles of PD-L1, PAPR1 and DLL3 in Small Cell Lung Cancer	Journal of Thoracic Oncology	Xiao Fu, Tao Tian et al.	1
18	Erlotinib has tumor inhibitory effect in human retinoblastoma cells	Biomedicine & Pharmacotherapy	Yi Shao, Yu Yao et al.	9
19	Effect of deferoxamine mesylate on occupied volume and 90 days prognosis in patients after intracerebral hemorrhage	Chinese Journal of Neuromedicine	Yu Sun, Wei Zhao et al.	1
20	CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line	World Journal of Surgical Oncology	Qi Zheng, Lingyu Zhao et al.	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact